Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBOS Group Limited ( (AU:EBO) ) just unveiled an update.
EBOS Group Limited has reported that 2,598 performance rights have lapsed under its existing executive or employee incentive arrangements. Following this change, the company now has 1,430,690 performance rights on issue, modestly reducing potential future equity dilution for shareholders and providing a small update on its long-term incentive structure.
The adjustment to the total number of performance rights reflects normal movements within EBOS’s remuneration and retention programmes tied to performance. While relatively minor in scale, such changes are closely watched by investors tracking capital management, employee incentives and potential impacts on future share capital.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a healthcare and medical products company operating across New Zealand and Australia. It is listed on both the NZX and ASX and plays a significant role in the regional healthcare supply chain through the distribution of pharmaceuticals and related healthcare services.
Average Trading Volume: 122,704
Technical Sentiment Signal: Sell
Current Market Cap: A$3.78B
For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.